Form 4: Arrowhead Director Sells Shares Under 10b5-1 Plan

Arrowhead Pharmaceuticals director Mauro Ferrari sold 8,750 shares of common stock for $56.39 per share on November 28, 2025, under a pre-arranged trading plan.

Summary

• Mauro Ferrari, a Director of Arrowhead Pharmaceuticals, Inc. (ARWR), reported a sale of common stock.
• The transaction involved the disposition of 8,750 shares of ARWR common stock.
• The sale occurred on November 28, 2025, at a price of $56.39 per share.
• Following this transaction, Mauro Ferrari directly beneficially owns 68,764 shares of common stock.
• The transaction was executed pursuant to a Rule 10b5-1 trading plan.
• The remaining beneficial ownership includes shares underlying Restricted Stock Units, some of which are still subject to vesting conditions.

Sentiment

Score: 5

Explanation: The sale by a director is generally a neutral to slightly negative signal, but the execution under a 10b5-1 plan mitigates concerns about opportunistic selling, making it an expected, non-eventful transaction.

Positives

• The transaction was conducted under a Rule 10b5-1 plan, which indicates a pre-scheduled sale and generally mitigates concerns about opportunistic selling based on inside information.

Negatives

• A director selling shares, even under a 10b5-1 plan, can sometimes be perceived negatively by the market as it reduces insider ownership.

Industry Context

This insider transaction is specific to Arrowhead Pharmaceuticals and does not directly reflect broader industry trends, though insider selling can sometimes be a minor indicator of management's perception of future stock performance relative to the sector.

Stakeholder Impact

• Shareholders: May perceive a slight negative signal due to reduced insider ownership, though the 10b5-1 plan lessens this impact.

Key Dates

Recommendation

The director's sale of shares, while reducing insider ownership, was executed under a pre-arranged 10b5-1 plan. This suggests a planned liquidity event rather than a reaction to new, negative material information. Therefore, this specific transaction alone does not provide a strong basis to change an investment thesis, warranting a 'hold' recommendation based solely on this filing.

Keywords

Arrowhead Pharmaceuticals, ARWR, Mauro Ferrari, Form 4, Insider Trading, Stock Sale, Director, 10b5-1 Plan, Biotechnology, Pharmaceuticals